Pertuzumab: Optimizing HER2 Blockade

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pertuzumab: optimizing HER2 blockade.

Pertuzumab has been approved by the U.S. Food and Drug Administration for use in combination with trastuzumab and docetaxel for the first-line treatment of patients with advanced HER2-positive (HER2(+)) breast cancer. Pertuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2 and inhibits heterodimerization of HER2 with other HER fam...

متن کامل

Dual HER2 Blockade.

a Department of Gynecology, Martin-Luther-University, Halle/Saale, Germany; b Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon; c Peter MacCallum Cancer Centre, Melbourne, Australia; d Department of Oncology and Radiotherapy, Medical University of Gda ’ nsk; Gdansk, Poland; e Helen Diller Family Comprehensive Cancer Center, Univers...

متن کامل

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

BACKGROUND In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the me...

متن کامل

Pertuzumab in the treatment of HER2+ breast cancer.

Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family. It has a unique and complimentary mechanism of action compared with trastuzumab, and the combination has resulted in the enhanced blockade of the HER signaling pathway. When pertuzumab was used in combin...

متن کامل

Pertuzumab: new hope for patients with HER2-positive breast cancer.

BACKGROUND Human epidermal growth factor receptor 2 (HER2) overexpression is detected in approximately 15% to 20% of all breast cancers (BCs). A revolutionary change in the prognosis of this subgroup of patients has occurred since trastuzumab therapy was introduced into daily clinical practice. However, because trastuzumab resistance is common, new molecules with complementary and/or synergisti...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Clinical Cancer Research

سال: 2013

ISSN: 1078-0432,1557-3265

DOI: 10.1158/1078-0432.ccr-13-0518